PANCREATIC CANCER

This early-phase study tested an experimental oral drug called IK-595 in 75 adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have specific RAS or RAF gene mutations. The goal was to check safety, find the right dose, and see if it shrinks tumor…

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had stopped responding …

This study tested a new approach for people with locally advanced pancreatic cancer that cannot be removed by surgery. Participants received a radioactive injection directly into the tumor along with standard chemotherapy, aiming to shrink the tumor and control the disease. Only …

This early-phase study tested a treatment called CAR T cells in people with advanced pancreatic cancer that could not be removed by surgery or had spread. The goal was to see if giving these specially engineered immune cells through a vein or directly into the abdomen was safe an…

This study aimed to see if adding the experimental drug BNT321 to standard chemotherapy (mFOLFIRINOX) could help prevent pancreatic cancer from coming back after surgery. It was designed for people whose tumors were completely removed. However, the trial was stopped early after e…

This study tested whether combining two drugs, trametinib and hydroxychloroquine, could help people with advanced pancreatic cancer whose disease had stopped responding to standard treatments. The goal was to see if the combination could slow cancer growth and understand how resi…

This study tested the drug niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific PALB2 gene mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stopped early, so results are …

This study tested a new drug called SOT102, alone or with standard chemotherapy, in 31 people with advanced pancreatic cancer. The goal was to find the safest dose and see if it helped shrink tumors. However, the trial was stopped early because of unexpected safety problems that …

This study tested a drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to other treatments. The goal was to see if the drug could shrink tumors. However, the trial was stopped earl…

This study tested a new drug called NUV-868, alone or combined with other cancer drugs (olaparib or enzalutamide), in people with advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer. The main goals were to check safety and find the right dose. The study was…

This study tested a new drug called TAK-500, given alone or with another drug (pembrolizumab), in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early…

This study looked at whether adding MR-guided radiation to standard chemotherapy could reduce pain from the main tumor in people with metastatic pancreatic cancer. It enrolled 9 adults whose cancer had not worsened after 8 weeks of chemo. The trial was terminated early, so result…

This study looked at genetic mutations in tumors from 565 people with advanced cancers of the digestive system, including liver, pancreas, and stomach. The goal was to see how often these mutations occur and whether they can help doctors choose more personalized treatments. The s…